Literature DB >> 25716332

How many cancer deaths could New Zealand avoid if five-year relative survival ratios were the same as in Australia?

Peter Sandiford1, Manar E Abdel-Rahman, Claudia Allemani, Michel P Coleman, Geeta Gala.   

Abstract

AIM: To determine how many Māori and non-Māori deaths might have been avoidable if cancer survival in New Zealand were as high as in Australia.
METHODS: Age-sex-tumour specific five-year relative survival ratios were calculated for cancer patients diagnosed with 27 tumour sites (representing about 92% of all cancers) in 2006-10. These were used to estimate the number of Māori, non-Māori and total deaths (and proportion of excess deaths) that would have been avoidable within five years of diagnosis had New Zealand's relative survival been equivalent to Australia's.
RESULTS: A total of 3,631 cancer deaths (726/year; 13.4% of excess deaths) could have been avoidable. Among 25 tumours where ethnic-specific results were estimated, there were 851 potentially avoidable deaths in Māori (24.9%) and 2,758 in non-Māori (11.8%). Breast, bowel, lung and prostate tumours made up 64% of avoidable deaths. Those with the highest proportions of avoidable deaths were thyroid (44.7%), prostate (35.5%), breast (30.0%) and uterus (23.5%). More than 50% of Māori melanoma, prostate, testis and thyroid cancer deaths were avoidable.
CONCLUSION: A significant number of cancer deaths could be avoidable if New Zealand achieved Australia's relative survival ratios. The proportion is much higher for Māori than for non-Māori. IMPLICATIONS: There is considerable scope to improve cancer outcomes in New Zealand.
© 2015 Public Health Association of Australia.

Entities:  

Keywords:  Māori; New Zealand; avoidable mortality; cancer; relative survival

Mesh:

Year:  2015        PMID: 25716332     DOI: 10.1111/1753-6405.12344

Source DB:  PubMed          Journal:  Aust N Z J Public Health        ISSN: 1326-0200            Impact factor:   2.939


  4 in total

1.  Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

Authors:  Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman
Journal:  Lancet       Date:  2018-01-31       Impact factor: 79.321

2.  Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts.

Authors:  Nishi Karunasinghe; Stefan Ambs; Alice Wang; Wei Tang; Shuotun Zhu; Tiffany H Dorsey; Megan Goudie; Jonathan G Masters; Lynnette R Ferguson
Journal:  PLoS One       Date:  2018-06-19       Impact factor: 3.240

3.  The Mortality-to-Incidence Ratio Is Not a Valid Proxy for Cancer Survival.

Authors:  Libby Ellis; Aurélien Belot; Bernard Rachet; Michel P Coleman
Journal:  J Glob Oncol       Date:  2019-05

4.  Impact of low-dose CT screening for lung cancer on ethnic health inequities in New Zealand: a cost-effectiveness analysis.

Authors:  Melissa McLeod; Peter Sandiford; Giorgi Kvizhinadze; Karen Bartholomew; Sue Crengle
Journal:  BMJ Open       Date:  2020-09-24       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.